Comparative Effectiveness of Novel Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation

Abstract

Abstract

Introduction

The most prevalent cardiac arrhythmia, atrial fibrillation (AF), is linked to a markedly increased danger of stroke and systemic embolism. There are new oral anticoagulant referred to as Novel Oral Anticoagulants (NOACs), which have also emerged as potential alternatives to the traditional anticoagulant drug warfarin that have been associated with better safety benefits in preventing strokes. This study was a comparison between Warfarin's effectiveness and safety and NOACs for nonvalvular atrial fibrillation patients. Atrial fibrillation (AF) is the most common heart arrhythmia and is a significant danger for systemic embolus and stroke. The primary treatment for stroke prevention is warfarin, but there are new drugs called Novel Oral Anticoagulants (NOACs) that are effective and may provide greater safety benefits. This study's The goal was to evaluate the efficacy and security of NOACs vs warfarin in atrial fibrillation without valve involvement.

Methodology

A 400-patient retrospective comparative cohort analysis was conducted patients with non-valvular 200 patients treated with NOACs and 200 patients treated with warfarin, who had atrial fibrillation. Data Hospital medical records were used to collect data from January 2021 to December 2024. The primary effectiveness outcome was either systemic embolism or ischemic stroke, whereas the primary safety consequence was significant bleeding. t-test for independent samples, Chi-square test, Kaplan-Meier survival analysis, and For statistical analysis, The log-rank test and Cox proportional hazards regression were employed. The definition of A p-value below 0.05 was considered statistically significant.

Patients receiving NOACs experienced significantly fewer ischemic stroke or systemic embolism events than those receiving warfarin (5.0% vs. 12.0%, p=0.012). Additionally, there was far less major bleeding in the NOAC group (6.0% vs. 14.0%, p=0.007). Intracranial hemorrhage, all-cause mortality, and hospitalization rates were significantly reduced among NOAC users. Kaplan-Meier analysis demonstrated superior The NOAC group's event-free survival (Log-rank p=0.005). Cox regression with multiple variables showed that NOAC therapy independently reduced the possibility of unfavorable clinical results (HR=0.48, 95% CI: 0.24–0.92, p=0.028).

Conclusion

Compared to warfarin, NOACs were safer and more effective for patients with non-valvular atrial fibrillation. Their usage was connected to fewer thromboembolic events, bleeding complications, mortality, and hospitalization, supporting their use as a preferred anticoagulant therapy in clinical practice.